You are here:Home-Research Areas-Neurological Disease-Stroke

Request The Product List ofStroke Stroke

Cat. No. Product Name CAS No. Information
PC-61501

NS-1209

245063-59-6

A selective, water-soluble, in vivo long-lasting AMPA antagonist with Ki of 43 nM; display selectivity for the [3H] AMPA over the [3H]kainate- (IC50=81 uM), [3H]CGS19755, and [3H]glycine-binding sites (IC50 > 30 uM) in rat cortical membranes; inhibits AMPA-induced currents in cortical neurons with IC50 of 0.15 uM; blocks AMPA-evoked spike activity in rat hippocampus (ED50=6.1mg/kg).

Stroke

Phase 2 Discontinued

PC-61011

DS-1040 tosylate hydrate

1335138-90-3

DS-1040 tosylate hydrate (DS1040) is a small molecule inhibitor of the activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC50 of 1.7 ng/mL for rabbit TAFIa; a novel fibrinolysis-enhancing agent has favorable pharmacokinetic/pharmacodynamic properties and a favorable safety profile

Stroke

Phase 2 Clinical

PC-61010

DS-1040 tosylate

1335138-89-0

DS-1040 tosylate (DS1040) is a small molecule inhibitor of the activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC50 of 1.7 ng/mL for rabbit TAFIa; a novel fibrinolysis-enhancing agent has favorable pharmacokinetic/pharmacodynamic properties and a favorable safety profile

Stroke

Phase 2 Clinical

PC-61009

DS-1040

1335138-62-9

DS-1040 (DS1040) is a small molecule inhibitor of the activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC50 of 1.7 ng/mL for rabbit TAFIa; a novel fibrinolysis-enhancing agent has favorable pharmacokinetic/pharmacodynamic properties and a favorable safety profile

Stroke

Phase 2 Clinical

PC-45282

Cilostazol

73963-72-1

Cilostazol (OPC 13013, OPC 21) is a potent inhibitor of PDE3A with IC50 of 0.2 uM; inhibits platelet aggregation and has considerable antithrombotic effects in vivo. The compound relaxes vascular smooth muscle and inhibits mitogenesis and migration of vascular smooth muscle cells; also upregulates autophagy via SIRT1 activation, has preventive effects on various central nervous system (CNS) diseases.

Stroke

Approved

PC-35544

S44819

1398496-82-6 S44819 (S-44819, Egis-13529) is a novel potent, competitive, selective antagonist of the α5-GABAAR with Kd of 221 nM, IC50 of 585 nM (α5β2γ2); does not inhibit the activation of α5-GABAARs by etomidate, displays week activity against α1β2γ2 (IC50=2.4 uM) and α3β2γ2 (IC50=3.7 uM); enhances hippocampal synaptic plasticity and exhibits pro-cognitive efficacy in vivo.

Stroke

Phase 2 Clinical

PC-35442

Amelparib hydrochloric hydrate

1449233-60-6 Amelparib hydrochloric hydrate (JPI-289, JPI289) is a novel potent, water soluble PARP-1 inhibitor with IC50 of 18.5 nM, inhibits cellular PAR formation with IC50 of 10.7 nM; does not affect cell viability up to 1 mM in rat cortical neuronal cells; attenuates PARP activity restores ATP and NAD+ levels in oxygen glucose deprived (OGD) rat cortical neurons, reduces apoptosis-associated molecules such as apoptosis inducing factor (AIF), cytochrome C and cleaved caspase-3 in the OGD model; JPI-289 is a potential neuroprotective agent which could be useful as a treatment for acute ischaemic stroke.

Stroke

Phase 2 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com